Clarissa Desjardins Acquires 1,130 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) Director Clarissa Desjardins purchased 1,130 shares of the business’s stock in a transaction that occurred on Wednesday, May 21st. The shares were purchased at an average price of $66.35 per share, for a total transaction of $74,975.50. Following the completion of the acquisition, the director now directly owns 3,025 shares in the company, valued at $200,708.75. The trade was a 59.63% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Clarissa Desjardins also recently made the following trade(s):

• On Tuesday, May 20th, Clarissa Desjardins purchased 1,895 shares of Insmed stock. The shares were purchased at an average price of $66.87 per share, for a total transaction of $126,718.65.

Insmed Stock Up 2.1%

Insmed stock opened at $67.53 on Friday. The business has a fifty day moving average of $70.69 and a two-hundred day moving average of $73.05. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The firm has a market cap of $12.30 billion, a P/E ratio of -12.08 and a beta of 0.84. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). The company had revenue of $92.82 million for the quarter, compared to analysts’ expectations of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm’s quarterly revenue was up 22.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.06) EPS. On average, analysts forecast that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a report on Wednesday, February 19th. Wells Fargo & Company boosted their price objective on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Guggenheim reaffirmed a “buy” rating and set a $101.00 target price on shares of Insmed in a research report on Tuesday, February 25th. Bank of America lifted their price target on shares of Insmed from $92.00 to $96.00 and gave the company a “buy” rating in a research note on Thursday, March 20th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $100.00 price target on shares of Insmed in a report on Wednesday, March 19th. One investment analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $94.63.

Institutional Trading of Insmed

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Insmed by 0.3% during the first quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company’s stock worth $1,393,675,000 after buying an additional 49,149 shares during the period. Darwin Global Management Ltd. lifted its holdings in Insmed by 23.5% during the fourth quarter. Darwin Global Management Ltd. now owns 12,960,538 shares of the biopharmaceutical company’s stock worth $894,796,000 after buying an additional 2,463,261 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Insmed by 1.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company’s stock worth $985,938,000 after buying an additional 219,131 shares during the period. Capital International Investors lifted its holdings in Insmed by 9.1% during the fourth quarter. Capital International Investors now owns 7,116,997 shares of the biopharmaceutical company’s stock worth $491,357,000 after buying an additional 593,206 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Insmed by 7.2% during the fourth quarter. Geode Capital Management LLC now owns 4,087,143 shares of the biopharmaceutical company’s stock worth $282,243,000 after buying an additional 273,759 shares during the period.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.